No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CADL240517C7000
- 3.58
- +0.78+27.86%
15min DelayClose May 14 15:59 ET
3.58High3.57Low
3.57Open2.80Pre Close9 Volume419 Open Interest7.00Strike Price3.21KTurnover602.78%IV5.14%PremiumMay 17, 2024Expiry Date3.70Intrinsic Value100Multiplier2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.8561Delta0.0397Gamma2.52Leverage Ratio-0.2348Theta0.0004Rho2.15Eff Leverage0.0021Vega
Intraday
- 5D
- 1D
News
Candel Therapeutics | 10-Q: Quarterly report
Express News | Candel Therapeutics Inc: Qtrly Shr Loss $0.28
Express News | Candel Therapeutics: Expects Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Current Operating Plan Into Q4
Candel Therapeutics 1Q Research and Development Expenses $4.1M >CADL
Candel Therapeutics 1Q Research and Development Expenses $4.1M >CADL
Express News | Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Express News | Candel Therapeutics Q1 Net Income USD -8.221 Million
Comments
$Candel Therapeutics(CADL.US$ . is set to make a significant impact at the upcoming 2024 American Society of Clinical Oncology Annual Meeting with two poster presentations highlighting their latest clinical trials.
1
1
$Candel Therapeutics(CADL.US$ next rnd
3
Read more
70959052OP : This will be legenadry 10x easy from here